Success Metrics

Clinical Success Rate
92.3%

Based on 12 completed trials

Completion Rate
92%(12/13)
Active Trials
1(7%)
Results Posted
75%(9 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_2
1
7%
Ph phase_3
10
71%
Ph not_applicable
1
7%
Ph phase_4
1
7%

Phase Distribution

0

Early Stage

1

Mid Stage

11

Late Stage

Phase Distribution13 total trials
Phase 2Efficacy & side effects
1(7.7%)
Phase 3Large-scale testing
10(76.9%)
Phase 4Post-market surveillance
1(7.7%)
N/ANon-phased studies
1(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.3%

12 of 13 finished

Non-Completion Rate

7.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

14

all time

Status Distribution
Active(1)
Completed(12)
Terminated(1)

Detailed Status

Completed12
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
1
Success Rate
92.3%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (7.7%)
Phase 310 (76.9%)
Phase 41 (7.7%)
N/A1 (7.7%)

Trials by Status

recruiting17%
terminated17%
completed1286%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT07160244Phase 3

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

Recruiting
NCT01627561Phase 3

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

Completed
NCT00148941Phase 3

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines

Completed
NCT02096263Phase 3

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

Completed
NCT00614614Phase 3

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

Completed
NCT00197236Phase 3

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

Completed
NCT01171963Phase 3

Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants

Completed
NCT01000974Phase 3

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

Completed
NCT00696423Phase 3

Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children

Completed
NCT00412854Phase 3

Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.

Completed
NCT00729001Phase 2

Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.

Completed
NCT00544271Phase 4

Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.

Terminated
NCT02447978

Duration of Protection: GSK DTaP Vaccines

Completed
NCT00482781Not Applicable

DTaP and Apnea/Bradycardia in Preterm Infants

Completed

All 14 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
14